Big Pharma partners join initiative to drive equity and inclusion in digital trials
As digital trials picked up steam amid the pandemic, some said the technology could also be used to address biopharma’s historic lack of diversity in the clinic. But if implemented the wrong way, it could also exacerbate the problem, the Digital Medicine Society (DiMe) warns.
That’s why DiMe is looking to create a framework and resources for successfully running digital trials. And a suite of industry players — including Amgen and GlaxoSmithKline — are joining the new initiative.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters